41 results on '"Asano, T."'
Search Results
2. Cobicistat, a potent CYP3A4 inhibitor, acts synergistically with oprozomib to cause endoplasmic reticulum stress in bladder cancer cells
3. Single-surgeon series of delayed anastomotic urethroplasty for pelvic fracture urethral injury: An analysis of surgical and patient-reported outcome of a 10-year experience in a Japanese referral center
4. The ataxia telangiectasia and Rad3 related kinase inhibitor AZD6738 sensitizes bladder cancer cells to gemcitabine
5. Metformin augments panobinostat’s antineoplastic activity in bladder cancer cells by activating AMP-activated protein kinase
6. Evaluation of the effect of urethroplasty for anterior urethral strictures by a validated disease specific patient-reported outcome measure
7. Ritonavir and oprozomib cause bladder cancer apoptosis synergistically by inducing endoplasmic reticulum stress
8. Regional distribution of lymph node metastasis in upper urinary tract urothelial cancer, sub-analysis of large multi-institutional study (JCOG1110A)
9. Panobinostat interacts with nelfinavir to inhibit renal cancer growth by causing endoplasmic reticulum stress
10. Ritonavir, a potent inhibitor of P-glycoprotein, enhances the anticancer effects of romidepsin in renal cancer cells
11. Panobinostat and ixazomib inhibit bladder cancer growth synergistically by increasing histone acetylation and inducing endoplasmic reticulum stress
12. The novel checkpoint kinase 1 inhibitor MK-8776 strongly sensitizes bladder cancer cells to gemcitabine
13. Lopinavir synergizes with ritonavir to induce bladder cancer apoptosis by causing histone acetylation and endoplasmic reticulum stress
14. 456 - Cobicistat, a potent CYP3A4 inhibitor, acts synergistically with oprozomib to cause endoplasmic reticulum stress in bladder cancer cells
15. 449 - The ataxia telangiectasia and Rad3-related kinase inhibitor AZD6738 overcomes cisplatin resistance in cisplatin-resistant bladder cancer cells
16. 795 Combination of human immunodeficiency virus protease inhibitors causes bladder cancer apoptosis synergistically by inducing endoplasmic reticulum stress and histone acetylation
17. 763 Clinical impact of the dose modification of second-line targeted therapy for patients with metastatic renal cell carcinoma
18. 122 Ritonavir and delanzomib inhibit renal cancer growth in vitro and in vivo by inducing endoplasmic reticulum stress synergistically
19. 801 The impact of ureteral ligation on clinical outcome during radical nephroureterectomy for upper urinary tract urothelial carcinoma: Multi-institutional case series study JCOG1110A
20. 1018 - Regional distribution of lymph node metastasis in upper urinary tract urothelial cancer, sub-analysis of large multi-institutional study (JCOG1110A)
21. 465 - Metformin augments panobinostat’s antineoplastic activity in bladder cancer cells by activating AMP-activated protein kinase
22. 459 - Ritonavir and oprozomib cause bladder cancer apoptosis synergistically by inducing endoplasmic reticulum stress
23. 456 - The ataxia telangiectasia and Rad3 related kinase inhibitor AZD6738 sensitizes bladder cancer cells to gemcitabine
24. 421 - Single-surgeon series of delayed anastomotic urethroplasty for pelvic fracture urethral injury: An analysis of surgical and patient-reported outcome of a 10-year experience in a Japanese referral center
25. 409 - Evaluation of the effect of urethroplasty for anterior urethral strictures by a validated disease specific patient-reported outcome measure
26. 759 Ritonavir synergizes with carfilzomib to cause endoplasmic reticulum stress and autophagy in bladder cancer cells
27. 971 - The novel checkpoint kinase 1 inhibitor MK-8776 strongly sensitizes bladder cancer cells to gemcitabine
28. 853 - Ritonavir, a potent inhibitor of P-glycoprotein, enhances the anticancer effects of romidepsin in renal cancer cells
29. 851 - Panobinostat interacts with nelfinavir to inhibit renal cancer growth by causing endoplasmic reticulum stress
30. 841 - Panobinostat and ixazomib inhibit bladder cancer growth synergistically by increasing histone acetylation and inducing endoplasmic reticulum stress
31. 833 - Lopinavir synergizes with ritonavir to induce bladder cancer apoptosis by causing histone acetylation and endoplasmic reticulum stress
32. 144 Bortezomib synergizes with vorinostat to cause ubiquitinated protein accumulation and histone acetylation in bladder cancer cells
33. 977 Ritonavir, a potent inhibitor of CYP3A4, enhances the anticancer effects of panobinostat in renal cancer cells in vitro and in vivo
34. 976 Panobinostat and bortezomib inhibit renal cancer growth in vitro and in vivo by inducing endoplasmic reticulum stress and ubiquitinated protein accumulation synergistically
35. 574 Detection of factors affecting early bladder recurrence after nephroureterectomy in patients with N0M0 upper urinary tract urothelial carcinoma
36. 827 Novel anticancer effect of proteasome inhibitor on prostate cancer cells targeting prostate-specific membrane antigen and androgen receptor
37. 57 Ritonavir and bortezomib inhibit bladder cancer growth by inducing endoplasmic reticulum stress and ubiquitinated protein accumulation synergistically
38. 240 Vorinostat interacts with bortezomib to enhance protein ubiquitination synergistically in prostate cancer cells
39. 205 Transactivation of the EGFR cell survival pathway under hypoxia mediates mTOR activation and induction of HIF-α proteins and resistance to rapamycin especially in wild-type VHL renal cell carcinoma
40. 739 RITONAVIR AND BORTEZOMIB INHIBIT RENAL CANCER GROWTH BY ENHANCING PROTEIN UBIQUITINATION SYNERGISTICALLY
41. 733 ENHANCED TRANSACTIVATION OF THE EGFR-ERK1/2 CELL SURVIVAL PATHWAY UNDER HYPOXIA CONFERS RESISTANCE TO RAPAMYCIN AND COULD BE A THERAPEUTIC TARGET IN RENAL CELL CARCINOMA
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.